Here in Berlin, we’re getting desperate for warmth and sunshine, so we moseyed on down to Barcelona to meet Minoryx Therapeutics. The company is developing a treatment for a peroxisomal disorder that leads to lifelong disability, and it’s about to enter Phase II/III.
City: Barcelona, Spain
Financial data: €24.4M total raised
Mission: Minoryx Therapeutics is focused on a group of rare genetic diseases like X-Linked Adrenoleukodystrophy (X-ALD) and other metabolic disorders that have no available treatment. The company is developing small molecules to address these diseases and sees them all the way through the clinic.
Comment: Minoryx is preparing to launch a Phase II/III trial for their X-linked adrenoleukodystrophy drug, MIN-102, early this year. To support the effort, it just recruited 5 new members to its Scientific Advisory Board from renowned institutions across Europe and the US.